DSM Opens New Biopharmaceutical Manufacturing Facility in Australia - - BioPharm International

ADVERTISEMENT

DSM Opens New Biopharmaceutical Manufacturing Facility in Australia



Untitled Document

DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, has opened a new cGMP facility for biopharmaceutical contract manufacturing in Brisbane, Australia. The facility was built in partnership with Biopharmaceuticals Australia with cooperation from the government of Queensland and the Commonwealth of Australia.

The Brisbane facility offers cGMP mammalian cell-culture contract manufacturing services from process development through to commercial manufacturing.
DSM Biologics, the business unit of DSM Pharmaceutical Products that operates the Brisbane facility, also offers process development and cGMP manufacturing in Groningen, The Netherlands. DSM previously announced contracts for the Brisbane site with DecImmune Therapeutics of Cambridge, Massachusetts, Recepta Biopharma of São Paulo, Brazil, Paranta Biosciences of Melbourne, Australia, and Opthea of Melbourne, Australia. The Brisbane facility has an output capability of 500 kg and has expansion space available for further capacity utilization.

Source: DSM Pharmaceutical

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here